STOCK TITAN

PETVIVO HOLDINGS INC - PETV STOCK NEWS

Welcome to our dedicated page for PETVIVO HOLDINGS news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on PETVIVO HOLDINGS stock.

PetVivo Holdings Inc (PETV) is an emerging biomedical device company with a focus on licensing and commercializing innovative medical devices for pets, known as pet therapeutics. The company aims to capitalize on investments in the human biomaterials and medical device industries to bring therapeutics to pets efficiently. As part of its strategy, PetVivo in-licenses proprietary products from human medical device companies for pet use. Its wholly-owned subsidiaries include PetVivo, Inc., Gel-Del Technologies, Inc., and CosmetaLife Corporation.

Rhea-AI Summary

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) will announce its financial results on February 10, 2022, after market close. A conference call is scheduled for the same day at 4:00 p.m. CT (5:00 p.m. ET), with a live webcast available on their Investor Relations website. The company focuses on innovative medical therapeutics for animals and holds a portfolio of 21 patents. Their lead product, SPRYNG™, designed for treating osteoarthritis in dogs and horses, was commercially launched in September 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
-
Rhea-AI Summary

PetVivo Holdings is set to present at the Emerging Growth Conference on January 19, 2022, from 11:30 AM to 12:00 PM Eastern. During this interactive session, CEO John Lai will discuss the company’s innovative biomedical devices for pets and answer audience questions. The conference aims to connect public companies with investors and includes a wide range of growth sectors.

PetVivo focuses on launching medical therapeutics for companion animals, with its lead product, Kush, targeting osteoarthritis in dogs and horses, anticipated for commercial release later this year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
conferences
-
Rhea-AI Summary

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announces its participation in the Veterinary Meeting & Expo Conference from January 15-19, 2022, in Orlando, FL. The company will showcase its lead product, Spryng with OsteoCushion Technology, designed to treat joint issues in pets, particularly osteoarthritis. With over 7,500 expected participants, the event presents an opportunity for PetVivo to network with industry leaders. The company's product is set for expanded commercial sales in Q4 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
none
Rhea-AI Summary

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) has announced a distribution agreement with VetCove, Inc. to market its therapeutic product, SPRYNG™ with OsteoCushion™ Technology. VetCove, utilized by over 13,000 veterinary hospitals, will enable easier access for veterinarians to order SPRYNG for pets suffering from osteoarthritis. This innovative device, comprised of micronized hydrogel matrices, aims to support joint health and alleviates lameness. PetVivo also holds a diverse pipeline of products, enhancing its position in the veterinary market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
-
Rhea-AI Summary

PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO John Lai will discuss the company's business overview on January 10 at 12:00 PM EST. PetVivo focuses on innovative medical devices for pets, including its lead product, SPRYNG, which targets joint issues in animals. The company holds 21 patents and plans for expanded commercial sale of SPRYNG in Q4 2022. For more details, visit PetVivo's official website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
-
Rhea-AI Summary

PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announced a successful showcase of its product, Spryng, at the American Association of Equine Practitioners (AAEP) conference from December 4-8, 2021. Spryng utilizes OsteoCushion Technology for treating lameness and joint issues like osteoarthritis. The company received positive feedback from veterinarians, indicating strong interest in adopting Spryng. PetVivo is offering a promotional deal through December 31, 2021, providing an extra syringe for every five purchased. The company plans expanded sales of Spryng in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags
none
Rhea-AI Summary

PetVivo Holdings, Inc. (NASDAQ: PETV) will participate in the American Association Equine Practitioners (AAEP) conference from December 4-8, 2021, in Nashville, TN. The company aims to showcase its lead product, SPRYNG, featuring OsteoCushion Technology, designed to treat lameness and joint issues, including osteoarthritis, in pets. The AAEP conference is expected to draw over 5,000 industry professionals, presenting opportunities for networking and business development. The company plans to expand commercial sales of SPRYNG in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
none
-
Rhea-AI Summary

PetVivo Holdings announces a comprehensive digital media campaign to promote its product Spryng™, targeting improvements in animal lameness. The campaign includes 40 interviews and 600 T.V. commercials over the next year on major networks like Newsmax and Bloomberg. Additionally, 2,400 digital billboard ads will be displayed daily in Manhattan. Spryng™, which aids osteoarthritis in pets, is set for expanded sales this quarter. PetVivo aims to leverage veterinary opportunities similar to human therapies, supported by a robust patent portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
Rhea-AI Summary

PetVivo Holdings raised approximately $11.25 million through an Initial Public Offering, rebranding Kush™ as Spryng™ and initiating sales. In Q2 2022, revenue reached $4,977, up from $4,790 in Q2 2021. The company reported a net loss of $1,105,474, improved from $1,348,002 in the same period last year. For the six months ended September 30, 2021, revenue was $9,122. The company aims to utilize offering proceeds to enhance sales and marketing efforts and has made key management hires.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.77%
Tags
Rhea-AI Summary

PetVivo Holdings, Inc. (Nasdaq: PETV, PETVW) raised approximately $11.25 million through an Initial Public Offering, rebranding Kush™ to Spryng™. As of September 30, 2021, revenues increased to $4,977 for Q2 2021 from $4,790 in Q2 2020. Net loss decreased to ($1,105,474) compared to ($1,348,002) year-over-year. Significant investments in sales, marketing, and research were made to support the launch of Spryng™. Key management hires were also announced.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.89%
Tags

FAQ

What is the current stock price of PETVIVO HOLDINGS (PETV)?

The current stock price of PETVIVO HOLDINGS (PETV) is $0.57 as of December 24, 2024.

What is the market cap of PETVIVO HOLDINGS (PETV)?

The market cap of PETVIVO HOLDINGS (PETV) is approximately 9.2M.

What is PetVivo Holdings Inc's focus?

PetVivo Holdings Inc focuses on licensing and commercializing innovative medical devices for pets, known as pet therapeutics.

How does PetVivo leverage investments in other industries?

PetVivo leverages investments in the human biomaterials and medical device industries to efficiently bring therapeutics to pets.

What is PetVivo's strategy regarding proprietary products?

PetVivo in-licenses proprietary products from human medical device companies specifically for use in pets.

What are the wholly-owned subsidiaries of PetVivo Holdings Inc?

PetVivo Holdings Inc's wholly-owned subsidiaries include PetVivo, Inc., Gel-Del Technologies, Inc., and CosmetaLife Corporation.

What is the goal of PetVivo Holdings Inc?

The goal of PetVivo Holdings Inc is to commercialize therapeutics for pets in a capital and time-efficient manner.

What industry does PetVivo Holdings Inc operate in?

PetVivo Holdings Inc operates in the biomedical device industry with a focus on pet therapeutics.

How does PetVivo Holdings Inc differentiate itself in the market?

PetVivo Holdings Inc differentiates itself by focusing on innovative medical devices for pets and leveraging investments in related industries.

Where is PetVivo Holdings Inc headquartered?

PetVivo Holdings Inc is headquartered in the United States.

What is the relationship between PetVivo Holdings Inc and Gel-Del Technologies, Inc?

Gel-Del Technologies, Inc is a wholly-owned subsidiary of PetVivo Holdings Inc.

What is the significance of CosmetaLife Corporation to PetVivo Holdings Inc?

CosmetaLife Corporation is a wholly-owned subsidiary of PetVivo Holdings Inc, playing a role in the company's operations.

PETVIVO HOLDINGS INC

Nasdaq:PETV

PETV Rankings

PETV Stock Data

9.18M
8.87M
54.85%
0.05%
0.77%
Medical Devices
Healthcare
Link
United States of America
Edina